A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Trial Profile

A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Gilteritinib (Primary)
  • Indications Acute myeloid leukaemia; Solid tumours
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 20 Jul 2017 Planned End Date changed from 1 Apr 2019 to 1 Oct 2019.
    • 20 Jul 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Oct 2019.
    • 12 Jun 2017 Planned End Date changed from 1 Mar 2019 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top